High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma

Journal of Neuro-Oncology

Volumn 101, Issue 3, 2011, Pages 345-355

  Campen, Christopher J ^a,b   Tombleson, Rebecca L ^c   Green, Myke R ^a,b  

^a UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Dose intensity; High dose chemotherapy; PCNSL; Primary CNS lymphoma; Stem cell transplantation

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PROCARBAZINE; THIOTEPA;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOENCEPHALOPATHY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PROGNOSIS;

EID: 79952188892     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0279-5     Document Type: Review

References (72)

1. Schabet M (1999) Epidemiology of primary CNS lymphoma. J Neuro-Oncol 43:199-201
2. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. J Clin Oncol 20:4643-4648 (Pubitemid 36025280)
3. Ferreri AJM, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512-1520
4. Plotkin SR, Batchelor TT (2001) Primary nervous-system lymphoma. Lancet Oncol 2:354-365 (Pubitemid 33585940)
5. Bhagavathi S, Wilson J (2008) Primary central nervous system lymphoma. Arch Pathol Lab Med 132:1830-1834
6. Ferrari AJM, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 21:266-272 (Pubitemid 46606155)
7. Abrey L, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the memorial sloan-kettering cancer center prognostic model. J Clin Oncol 24:5711-5715 (Pubitemid 46631313)
8. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570-4574 (Pubitemid 46630953)
9. Green MR, Chowdhary S, Lombardi KM, Chalmers LM, Chamberlain M (2006) Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 6:635-652 (Pubitemid 43964714)
10. Nguyen PL, Chakravarti A, Finkelstein DM et al (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23:1507-1513
11. Plotkin SR, Betensky RA, Hochberg FH et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10:5643-5646 (Pubitemid 39180936)
12. Reni M, Ferreri AJM, Landoni C, Villa E (2000) Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92:575-576 (Pubitemid 30212321)
13. Reni M, Mason W, Zaja F et al (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40:1682-1688 (Pubitemid 38902903)
14. Reni M, Zaja F, Mason W et al (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96:864-867 (Pubitemid 46452291)
15. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901-903 (Pubitemid 39297656)
16. Wong ET, Tishler R, Barron L, Wu J (2004) Immunochemotherapy with rituximab and temozolomide for PCNSL. Cancer 101:139-145
17. 90Y-ibritumomab and temozolomide. J Neurooncol 83:291-293
18. Fischer L, Thiel E, Klasen HA, Kirchen H, Jahnke K, Korfel A (2004) Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62:1885-1887 (Pubitemid 38661760)
19. Fischer L, Thiel E, Klasen HA et al (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141-1145
20. Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neuro-Oncol 86:211-215 (Pubitemid 350263420)
21. Arellano-Ridrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70:219-224 (Pubitemid 36469758)
22. Yamanaka R, Homma J, Sano M et al (2007) Salvage immunochemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study. Leuk Lymphoma 48:1429-1433 (Pubitemid 47079376)
23. Herrlinger U, Brugger W, Bamberg M, Küker W, Dichgans J, Weller M (2000) PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54(8):1707-1708 (Pubitemid 30226828)
24. Goldspiel B (2004) Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma. Pharmacotherapy 24:1347-1357
25. Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree structured survival analysis. J Clin Oncol 8:963-977 (Pubitemid 20200184)
26. Epelbaum R, Faraggi D, Ben-Arie Y et al (1990) Survival of diffuse large cell lymphoma. A multi-variate analysis including dose intensity variables. Cancer 66:1124-1129
27. Tilly H, Lepage E, Coiffier B et al (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289 (Pubitemid 37494085)
28. Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633 (Pubitemid 38970553)
29. Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641 (Pubitemid 38970554)
30. Holmberg LA, Stewart FM (2006) Revisiting the role of dose intensity in hematological malignancies. Exp Hematol 34:811-825
31. Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545
32. Milpied N, Deconinck E, Gaillard F et al (2004) Groupe Ouest- est des Leucémies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287-1295 (Pubitemid 38375363)
33. Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T (2003) Long term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neuro-Oncol 63:87-95 (Pubitemid 36681648)
34. Illerhaus G, Marks R, Müller F et al (2009) High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 20:319-325
35. Joerger M, Huitema ADR, Krähenbühl S et al (2010) Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 102:673-677
36. Ferreri AJ, Guerra E, Regazzi M et al (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90:353-358 (Pubitemid 38250628)
37. de Boer AG, Gaillard PJ (2007) Drug targeting to the brain. Ann Rev Pharmacol Toxicol 47:325-355
38. Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancies: a reality check. J Clin Oncol 25:2295-2305 (Pubitemid 46954658)
39. Fliessbach K, Helmstaedter C, Urbach H et al (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma. Neurology 64:1184-1188
40. Herrlinger U, Schabet M, Bitzer D, Petersen D, Krauseneck P (1999) Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 43:219-226 (Pubitemid 29488378)
41. Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12:627-642 (Pubitemid 24079908)
42. Armstrong CL, Hunter JV, Ledakis GE et al (2002) Late cognitive and radiographic changes related to radiotherapy. Neurology 59:40-48 (Pubitemid 34742792)
43. DeAngelis LM, Shapiro WR (1991) Drug/radiation interactions and central nervous system injury. In: Gutin PH, Leibel SA, Sheline GE (eds) Radiation injury to the central nervous system. Raven Press, New York, pp 361-382
44. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548-555 (Pubitemid 38252794)
45. Omuro AMP, Ben-Porat LS, Panageas KS et al (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595-1600 (Pubitemid 41434567)
46. Ferreri AJ, Reni M (2007) Primary central nervous system lymphoma. Crit Rev Oncol Hematol 63:257-268 (Pubitemid 47126863)
47. Ferreri AJ, Abrey LE, Blay JY et al (2003) Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21:2407-2414 (Pubitemid 46621879)
48. Blay JY, Conroy T, Chevreau C et al (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864-871 (Pubitemid 28108718)
49. Reni M, Ferreri AJ, Garancini MP, Villa E (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8:227-234 (Pubitemid 27153487)
50. Batchelor T, Carson K, O'Neill A et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21:1044-1049 (Pubitemid 46594133)
51. Mehnert A, Scherwath A, Schimer L et al (2007) The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 66:108-118 (Pubitemid 46366616)
52. Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H (1996) Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transpl 18:1021-1023 (Pubitemid 26395222)
53. Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281-1288 (Pubitemid 46622031)
54. Soussain C, Suzan F, Hoang-Xuan K et al (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742-749 (Pubitemid 32119089)
55. Soussain C, Hoang-Xuan K, Taillandier L et al (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26:2512-2518
56. Patte C, Leverger G, Perel Y et al (1990) Updated results of the LMB86 protocol of the French Pediatric Oncology Society (SFOP) for B-cell non-hodgkin's lymphoma (B-NHL) with CNS involvement (CNS+) and B-ALL. Med Pediatr Oncol 18:406 (abstr)
57. Gerstner E, Batchelor T (2007) Primary CNS lymphoma. Expert Rev Anticanc Ther 7:689-700 (Pubitemid 46805564)
58. Abrey LE, Moskowitz CH, Mason WP et al (2001) A phase II study of intensive methotrexate and cytarabine followed by high dose BEAM chemotherapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL). Proc Am Soc Clin Oncol 20:A2055 (abstr 207)
59. Abrey LE, Moskowitz CH, Mason WP et al (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21:4151-4156 (Pubitemid 46606183)
60. Ferreri AJ, Crocchiolo R, Assanelli A, Govi S, Reni M (2008) High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 49:2042-2047
61. Wiebe VJ, Smith BR, Degregorio MW, Rappeport JM (1992) Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 13:241-270 (Pubitemid 23000148)
62. Holthus JM, Postmus PE, Van Oort WJ et al (1986) Pharmacokinetics of high-dose etoposide (VP16-213). Eur J Cancer Clin Oncol 22:1149-1155
63. Gouyette A, Hartmann O, Pico JL (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16:184-189 (Pubitemid 16155992)
64. Ho DHW, Frei E III (1971) Clinical pharmacology of 1-B-D-arabinofuranosyl cytosine. Clin Pharmacol 12:944-954
65. Breithaupt H, Pralle H, Eckhardt T, von Hattingberg M, Schick J, Löffler H (1982) Clinical results and pharmacokinetics of highdose cytosine arabinoside (HD ARA-C). Cancer 50:1248-1257 (Pubitemid 12031943)
66. Cheng T, Forsyth P, Chaudhry A et al (2003) High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transpl 31:679-685 (Pubitemid 36553478)
67. Brevet M, Garidi R, Gruson B, Royer B, Vaida I, Damaj G (2005) First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 75:288-292 (Pubitemid 41297604)
68. Colombat P, Lemevel A, Bertrand P et al (2006) High-dose chemotherapy with autologous stem cell transplantation as firstline therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transpl 38:417-420 (Pubitemid 44340371)
69. Illerhaus G, Marks R, Ihorst G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865-3870 (Pubitemid 46630733)
70. Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93:147-148 (Pubitemid 351156168)
71. Montemurro M, Kiefer T, Schüler F et al (2007) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hämato-Onkologie OSHO-53 phase II study. Ann Oncol 18:665-671 (Pubitemid 46523269)
72. Varadi G, Or R, Kapelushnik J et al (1999) Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma 34:185-190 (Pubitemid 29248675)